NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
Back to Newsroom
Mentioned in this Article

NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference

Friday, September 24, 2021 8:15 AM
Share this article now
Topic:
Conferences
NLS Pharmaceutics AG

STANS, SWITZERLAND / ACCESSWIRE / September 24, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Chief Executive Officer and Co-Founder Alex Zwyer is scheduled to participate in a live interview and meet with investors at the Benzinga Healthcare Small Cap Conference to be held virtually on September 29-30, 2021.

Event Details:

Date: September 29, 2021
Time: 1:55pm - 2:15pm ET

Event Access: Please click this link to access the live interview. A replay will also be available on the Company's website at https://nls-pharma.com/

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS has recently initiated a phase 2 study in the U.S. evaluating Quilience® in adult subjects suffering from Narcolepsy. Previously, NLS successfully completed a phase 2 study in the U.S. evaluating Nolazol® (mazindol controlled-release) in adult subjects suffering from ADHD. The study met all primary and secondary endpoints and Nolazol® was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3rd of narcoleptic patients are also diagnosed with ADHD.

Corporate Contact
Alex Zwyer, CEO
+41 41 618 80 00

Investor Relations Contact
Cindy Rizzo 
+1 908-229-7050
www.nlspharma.com

SOURCE: NLS Pharmaceutics AG

Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions